×
About 4,765 results

ALLMedicine™ Thrombotic Thrombocytopenic Purpura Center

Research & Reviews  2,287 results

Double positivity of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothr...
https://doi.org/10.1007/s11239-021-02406-6 10.1111/j.1538-7836.2006.01753.x 10.1056/NEJMra1705454 10.1515/cclm-2017-0502 10.1515/cclm-2016-0676 10.1177/0961203315579091 10.1155/2018/3287491 10.1016/j.thromres.2017.07.001 10.1097/mbc.0000000000000512 10.1182/blood-2004-11-4490 10.1182/blood-2003-05-1616 10.1111/j.1365-2141.2008.07074.x
Journal of Thrombosis and Thrombolysis; Yun J, Gu J et. al.

Apr 29th, 2021 - Although a few antiphospholipid syndrome (APS) occurs with acquired thrombotic thrombocytopenic purpura (TTP), the relationship between antiphospholipid antibodies (aPL) and anti-ADAMTS13 (anti-a disintegrin and metalloprotease with thrombospondin...

COVID 19 infection associated with thrombotic thrombocytopenic purpura.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075832
Journal of Thrombosis and Thrombolysis; Dhingra G, Maji M et. al.

Apr 27th, 2021 - Thrombotic thrombocytopenic purpura (TTP) which can cause significant mortality is a thrombotic microangiopathy due to deficiency of VWF cleaving protease ADAMTS13 and as per medical literature there are examples that TTP can be caused by COVID 19...

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytope...
https://doi.org/10.1182/bloodadvances.2020001834
Blood Advances; Peyvandi F, Cataland S et. al.

Apr 21st, 2021 - The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 TITAN and phase 3 HERCULES trials. Integrated analysis of data from both trials was conducted to i...

Post-cardiac surgery thrombotic thrombocytopenic purpura: presence of anti-ADAMTS13 aut...
https://doi.org/10.1080/09537104.2021.1912314
Platelets Tordon B, Warkentin TE et. al.

Apr 14th, 2021 - Thrombotic thrombocytopenic purpura (TTP) rarely complicates acute inflammatory conditions such as surgery, including post-cardiac surgery. Review of 32 previously-reported cases of post-cardiac surgery TTP indicates that this disorder often occur...

see more →

Guidelines  11 results

CABLIVI (caplacizumab-yhdp) Prescribing Information
http://products.sanofi.us/cablivi/cablivi.pdf

Feb 5th, 2019 - CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

FDA approves Cablivi, first treatment for acquired thrombotic thrombocytopenic purpura
https://www.healio.com/hematology-oncology/hematology/news/online/%7Be91d83f6-8859-412b-970c-198151f0b208%7D/fda-approves-cablivi-first-treatment-for-acquired-thrombotic-thrombocytopenic-purpura
Pazdur,R.

Feb 5th, 2019 - The FDA today approved caplacizumab-yhdp injection as the first therapy specifically indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura, a rare and life-threatening blood clotting disorder.

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
http://hugin.info/152918/R/2233733/878824.pdf

Feb 5th, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the firs...

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
https://www.nejm.org/doi/10.1056/NEJMoa1806311
Scully,M.,et al

Jan 23rd, 2019 - In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which re...

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
https://www.jwatch.org/na48305/2019/01/17/caplacizumab-acquired-thrombotic-thrombocytopenic-purpura
Green,David

Jan 16th, 2019 - Patients with acquired thrombotic thrombocytopenic purpura (TTP) have von Willebrand factor (VWF)–mediated platelet aggregates that ...HERCULES Trial

see more →

Drugs  17 results see all →

Clinicaltrials.gov  2,343 results

Double positivity of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothr...
https://doi.org/10.1007/s11239-021-02406-6 10.1111/j.1538-7836.2006.01753.x 10.1056/NEJMra1705454 10.1515/cclm-2017-0502 10.1515/cclm-2016-0676 10.1177/0961203315579091 10.1155/2018/3287491 10.1016/j.thromres.2017.07.001 10.1097/mbc.0000000000000512 10.1182/blood-2004-11-4490 10.1182/blood-2003-05-1616 10.1111/j.1365-2141.2008.07074.x
Journal of Thrombosis and Thrombolysis; Yun J, Gu J et. al.

Apr 29th, 2021 - Although a few antiphospholipid syndrome (APS) occurs with acquired thrombotic thrombocytopenic purpura (TTP), the relationship between antiphospholipid antibodies (aPL) and anti-ADAMTS13 (anti-a disintegrin and metalloprotease with thrombospondin...

COVID 19 infection associated with thrombotic thrombocytopenic purpura.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075832
Journal of Thrombosis and Thrombolysis; Dhingra G, Maji M et. al.

Apr 27th, 2021 - Thrombotic thrombocytopenic purpura (TTP) which can cause significant mortality is a thrombotic microangiopathy due to deficiency of VWF cleaving protease ADAMTS13 and as per medical literature there are examples that TTP can be caused by COVID 19...

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytope...
https://doi.org/10.1182/bloodadvances.2020001834
Blood Advances; Peyvandi F, Cataland S et. al.

Apr 21st, 2021 - The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 TITAN and phase 3 HERCULES trials. Integrated analysis of data from both trials was conducted to i...

Post-cardiac surgery thrombotic thrombocytopenic purpura: presence of anti-ADAMTS13 aut...
https://doi.org/10.1080/09537104.2021.1912314
Platelets Tordon B, Warkentin TE et. al.

Apr 14th, 2021 - Thrombotic thrombocytopenic purpura (TTP) rarely complicates acute inflammatory conditions such as surgery, including post-cardiac surgery. Review of 32 previously-reported cases of post-cardiac surgery TTP indicates that this disorder often occur...

see more →

News  107 results

NICE Recommends Innovative Treatment for Severe Blood Disorder for NHS Use
https://www.medscape.com/viewarticle/941022

Nov 15th, 2020 - A brand-new treatment – one of the first for 25 years – for acute acquired thrombotic thrombocytopenic purpura (aTTP) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine use in the NHS. Caplacizumab (Ca...

2019 at a glance: Hem-onc U.S. drug approvals
https://www.mdedge.com/jcomjournal/article/211340/mixed-topics/2019-glance-hem-onc-us-drug-approvals/page/0/1?channel=325

Oct 31st, 2019 - Caplacizumab-yhdp (Cablivi) Class: Monoclonal antibody fragment directed against von Willebrand factor. Disease: Thrombotic thrombocytopenic purpura.

In older patients with immune-mediated TTP, atypical features may delay diagnosis
https://www.mdedge.com/hematology-oncology/article/209753/bleeding-disorders/older-patients-immune-mediated-ttp-atypical?channel=39313
Andrew D. Bowser

Oct 9th, 2019 - Older patients with immune thrombotic thrombocytopenic purpura (iTTP) more often have an atypical neurological presentation, which could result in a delayed diagnosis, according to authors of a recent retrospective analysis. “Practitioners should.

TTP death linked to elevated troponin and neurological signs
https://www.mdedge.com/internalmedicine/article/199586/bleeding-disorders/ttp-death-linked-elevated-troponin-and?channel=285
Will Pass

Apr 25th, 2019 - GLASGOW – Neurological abnormalities and elevated troponin predict mortality in patients with thrombotic thrombocytopenic purpura (TTP), according to retrospective analysis of 475 patients from the United Kingdom TTP registry. Will Pass/MDedge New.

Novel Assay Reveals Optimal Treatment in Rare Blood Disorder
https://www.staging.medscape.com/viewarticle/911288

Apr 3rd, 2019 - GLASGOW — Combining prophylactic infusions and anti-platelet therapy normalises thrombus formation in patients with congenital thrombotic thrombocytopenic purpura (TTP) under shear flow conditions, reveals a novel assay developed by UK researchers...

see more →